Palvella Therapeutics, Inc. (PVLA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$156.85-3.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PVLA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
• The Company remains on track to complete the NDA submission in the second half of 2026.
Stated in 3 of 3 supplied quarters. Management reported: “• The Company remains on track to complete the NDA submission in the second half of 2026.” “The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.” Operating income was $-21.405 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“• The Company remains on track to complete the NDA submission in the second half of 2026.”
“• NDA submission remains on track for the second half of 2026.”
“Elbow Elbow * * * * * * Statistically significant across key clinician-assessed individual signs of microcystic LM at week 12 Height (p<0.0001) Leaking (p<0.005) Bleeding (p<0.05) Erythema (p<0.005)…”
Completion of the NDA submission remains on track for the second half of 2026, and we are preparing for a planned standalone commercial launch in the first half of 2027, if approved.
Stated in 3 of 3 supplied quarters. Management reported: “Completion of the NDA submission remains on track for the second half of 2026, and we are preparing for a planned standalone commercial launch in the first half of 2027, if approved.” “Preparing for Potential U.S. Commercial Launch in 2027 Palvella is preparing for a potential standalone U.S. commercial launch of QTORIN™ rapamycin in the first half of 2027, subject to FDA approval.”
“Completion of the NDA submission remains on track for the second half of 2026, and we are preparing for a planned standalone commercial launch in the first half of 2027, if approved.”
““Following the positive Phase 3 SELVA topline results, we believe Palvella is on a clear path toward near-term NDA submission for QTORIN™ rapamycin in microcystic lymphatic malformations, with the po…”
“: A Clear Path Forward for Patients QTORIN™ Rapamycin at Week 24: Highly statistically significant across primary, key secondary, and all four secondary endpoints (all p<0.001) +2.13 Mean improvement…”
QTORIN™ rapamycin and QTORIN™ platform expansion • Palvella plans to announce the fourth target clinical indication for QTORIN™ rapamycin in the second half of 2026.
Stated in 3 of 3 supplied quarters. Management reported: “QTORIN™ rapamycin and QTORIN™ platform expansion • Palvella plans to announce the fourth target clinical indication for QTORIN™ rapamycin in the second half of 2026.” “QTORIN™ rapamycin and QTORIN™ platform expansion • Plan to announce the third product candidate from the QTORIN™ platform in a serious, rare disease with no FDA-approved therapies in the second half of 2026.”
“QTORIN™ rapamycin and QTORIN™ platform expansion • Palvella plans to announce the fourth target clinical indication for QTORIN™ rapamycin in the second half of 2026.”
“QTORIN™ rapamycin and QTORIN™ platform expansion • Plan to announce the third product candidate from the QTORIN™ platform in a serious, rare disease with no FDA-approved therapies in the second half…”
“Oral rapamycin is not a viable therapeutic option in skin diseases: Systemic toxicities & low biodistribution to the skin Microcystic LMs Cutaneous VMs Clinically Significant Angiokeratomas Additiona…”
ET today WAYNE, Pa., August 4, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc .
Stated in 2 of 3 supplied quarters. Management reported: “ET today WAYNE, Pa., August 4, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc .” “ET today WAYNE, PA., May 7, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today reported financial results for the first quarter ending March 31, 2026 and provided a corporate update.”
“ET today WAYNE, Pa., August 4, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc .”
“ET today WAYNE, PA., May 7, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and comme…”
Build commercial, medical affairs, and patient services capabilities for a potential standalone U.S. launch of QTORIN rapamycin, subject to FDA approval.
Over the trailing year it converted -0.43x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 34% of the time over the next year (vs 53% for the rest of the cohort, n=2525).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.